<DOC>
	<DOCNO>NCT00554255</DOCNO>
	<brief_summary>To investigate safety tolerability , PK PD SB751689 follow single 5-day multiple oral dos 100 , 200 , 400 mg Japanese postmenopausal subject .</brief_summary>
	<brief_title>A Study SB751689 Japanese Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<criteria>The subject consider healthy investigator screen . Healthy subject define individual free clinically significant illness disease determine medical history , physical examination , laboratory study , test Japanese healthy postmenopausal woman define amenorrheic least 1 year screen &lt; 157.79mIU/mL FSH level . Body weight &gt; = 45 kg BMI within range 18.5 25.0 kg/m2 . The subject within follow criterion screen ; Liver function test ( ALT , AST , GGT , alkaline phosphatase , total bilirubin ) , CPK , serum parathyroid hormone ( iPTH ) test , vitamin D ( 1,25 ( OH2 D3 ) ) level , Serum calcium Capable give write informed consent , include compliance requirement restriction list consent form . Nonsmokers ( least 6 month ) The subject able attend visit complete study . The subject clinically relevant abnormality medical examination , vital sign , clinical laboratory test medical history screen medical opinion investigator subject medical history consider eligible inclusion study investigator . History sensitivity study medication component thereof ( except pollenosis without sign symptom ) . Participation clinical study postmarketing study investigational noninvestigational product device within 4 month precede first dose study medication . Participation another clinical study postmarketing study subject expose investigational noninvestigational product device . Positive syphilis , HIV antibody , hepatitis B antigen hepatitis C antibody , HTLV1 antibody screen . Positive urine drug screen screen . Donation blood excess 400 mL within previous 4 month 200mL within previous 1 month screening . Use prescription nonprescription drug , herbal dietary supplement , within 14 day prior first dose study medication . History drug abuse current condition drug abuse alcoholism . History regular alcohol consumption exceed 7 units/week ( &gt; 350mL beer/unit ) within 6 month screen . Subjects history renal , hepatic , biliary disease . History clinically significant cardiovascular disease . History pernicious anemia , pancreatitis , osteosarcoma kidney stone . Subjects history significant gastrointestinal disease ( e.g. , gastrointestinal malabsorptive disease , colostomy , chronic gastroesophageal reflux disease , Crohn 's disease , ulcerative colitis , gastric duodenal ulcer , gastrointestinal tract bleeding , short bowel syndrome , sprue , lactose intolerance , irritable bowel syndrome ) . Subjects history gastrointestinal surgical procedure might affect absorption SB751689 ( e.g . cholecystectomy , gastrointestinal bypass surgery , partial total gastrectomy , small bowel resection ) . Medical condition might alter bone metabolism , include hyperparathyroidism , hypoparathyroidism , hyperthyroidism , hypothyroidism , Paget 's disease , malabsorption , Cushing 's syndrome , hypogonadism , hypocalcemia , hypercalcemia , hypophosphatemia , hypomagnesemia , hypermagnesemia , osteopetrosis , osteomalacia , recent ( within one year ) history fracture prolong bedrest .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Japanese</keyword>
	<keyword>safety</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>